GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.98 USD | +1.11% |
|
+3.95% | -5.84% |
| 15/05 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
| 15/05 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
ETFs positioned on Genmab A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.28% | 1 M€ | +0.15% | - | |
| 1.99% | 0 M€ | 0.00% | - | |
| 1.68% | 0 M€ | 0.00% | - | |
| 1.47% | 9 M€ | -4.31% | - |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,041
DKK
Average target price
2,470
DKK
Spread / Average Target
+21.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.42% | 11TCr | |
| +11.84% | 11TCr | |
| -2.74% | 2.2TCr | |
| -14.15% | 2.19TCr | |
| -4.16% | 1.81TCr | |
| -38.29% | 1.77TCr | |
| +7.99% | 1.43TCr | |
| +36.24% | 1.24TCr | |
| -24.95% | 823.19Cr |
- Stock Market
- Equities
- GMAB Stock
- GMAB Stock
- Funds and ETFs Genmab A/S
